Compare Merck & Co., Inc. (MRK) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Taskus Inc — how do they compare? Merck & Co., Inc. trades at $130.73 (market cap $323.00B), while Taskus Inc trades at $7.03 (market cap $650.52M). The key difference: Merck & Co., Inc. is far larger — about 496.5× Taskus Inc's market cap, and Merck & Co., Inc. pays a 2.6% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| MRK | TASK | |
|---|---|---|
Market Cap | $323.00B | $650.52M |
Sector | Health | Technology |
52-Week High | $131.84 | $18.21 |
52-Week Low | $77.60 | $4.57 |
Enterprise Value | $369.77B | $1.02B |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $130.51, up 1.51% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $139.90. Recent earnings beats in Q4 2025 and Q1-Q2 2026 highlight operational strength, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock shows robust cash flow from operations of $16.47B in 2025, though a high P/E ratio of 104.74 signals premium valuation.
The outlook for MRK is positive, driven by strategic M&A and earnings momentum, but risks include patent expirations and regulatory pressures. Investors may find opportunity in its dividend yield and growth initiatives, yet should weigh elevated valuation against potential headwinds from competitive and macroeconomic factors.
TaskUs (TASK) trades at $7.30, down 6.65% today, but maintains strong fundamentals with Q2 2026 revenue beating guidance by $10.9 million. The stock shows bullish technical signals with support at $7 and bullish moving averages. Valuation metrics appear attractive with P/E of 6.29 and P/S of 0.55, while profitability remains solid with 8.75% net margin and 25.43% ROE. Recent CFO appointment and AI services growth provide positive catalysts.
The outlook remains positive with analyst consensus favoring Buy ratings (54.55%) and improving cash flow trends. Key opportunities include undervaluation relative to earnings power and AI services expansion. Risks include client concentration and potential earnings volatility. The combination of reasonable valuation and growth momentum supports a constructive view for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
